Growing middle class popping more pills, worrying antibiotic study shows
Pill popping up more than a third in 10 years, mostly through overuse, raising fears of rising global vulnerability to drug-resistant bacteria
Antibiotic use has surged by 36 per cent worldwide in a decade, much of it unwarranted, reveals a new study.
A few countries experiencing economic growth - China, Brazil, Russia, India, and South Africa - accounted for more than three-quarters of the rise.
The increase, particularly in countries with a burgeoning middle class, heightens concerns that overuse of antibiotics is leaving more of the world's population vulnerable to drug-resistant bacteria.
The study, published online in the journal Lancet Infectious Diseases, provides the most comprehensive long-term view of antibiotic use in 71 countries from 2000 to 2010.
It found the rise in consumption could not be explained by population changes alone and appeared to run parallel with economic development.
"People are getting richer and can afford antibiotics," said Thomas Van Boeckel, a Princeton University epidemiologist and lead author of the study.
"That is not necessarily all bad news. People need access to antibiotics. But there is appropriate use and misuse."
Among the results researchers found most troubling was the sharp rise in consumption of broad-spectrum antibiotics that are normally considered a measure of last resort.
Among them are carbapenems, such as ampicillin and amoxicillin, and polymyxins, both often used against enterobacteria such as salmonella and shigella.
Hospitals worldwide have struggled with serious outbreaks of carbapenem-resistant enterobacteriaceae, or CRE, as well as methicillin-resistant Staphylococcus aureus, or MRSA.
"If we lose the effectiveness of these drugs, there really isn't much left," Van Boeckel said.
The study was not set up to distinguish inappropriate use of antibiotics, a phenomenon that has been well established by other studies. But some trends in the data suggest that antibiotics may be inappropriately prescribed.
For instance, the authors note, a rise in use of cephalosporins and fluoroquinolones in low- and middle-income countries probably comes in response to acute diarrhoeal illnesses and to such fever-producing maladies as dengue and chikungunya, even though most of these are caused by viruses, which do not respond to antibiotics.
Higher use of antibiotics also coincides with the influenza virus season, even though they are ineffective as a treatment against the flu, Van Boeckel said.
"If you look at antibiotic use in the US, it's correlated to influenza, and it's not going to do anything for that," he said.
Although overall consumption of antibiotics fell in Europe and the US over the decade studied, largely due to public awareness campaigns, the US remains a very high consumer of antibiotics on a per-person basis. Per capita consumption also increased substantially in Australia and New Zealand, and all of the high-income Asian countries ranked among the top per capita consumers.
Within Europe, there were sharp differences between two nations of similar economic background. The French use three times the amount of antibiotics as do the Dutch.
In less affluent countries, however, public health authorities appear to be using antibiotics instead of making long-term improvements to sanitation, the authors said.
Such a strategy is short-sighted and counterproductive, leaving countries with the same exposure to much more resistant pathogens, they warned.
Van Boeckel and his co-authors called for international guidelines governing the prescription and sale of antibiotics and a uniform system for reporting antibiotic use. "The more we wait, the more resistance builds up," Van Boeckel said.